This introductory video explains how the FDA’s accelerated approval pathway works and why it is critical for helping people living with rare diseases access promising therapies sooner. Learn how surrogate endpoints are used to support earlier treatment access while additional research continues.
New Name, Same Commitment to Rare Diseases
The EveryLife Foundation for Rare Diseases has become The RARE Foundation! Read more about our new brand and how it unifies our advocacy work on behalf of the rare disease community.
